In Q2 2025, CervoMed posted $1.76M in grant revenue and a net loss of $6.26M, driven by increased R&D and G&A expenses. EPS was -$0.70. Cash and marketable securities totaled approximately $33.5M at quarter-end, providing at least 12 months of runway while the company prepares for an FDA Phase 3 design meeting for neflamapimod in DLB in Q4 2025.

CervoMed Inc. reported a net loss of $4,894,034 for the three months ended March 31, 2025, compared to a net loss of $2,514,335 for the same period in 2024. The company's grant revenue decreased, while operating expenses, particularly research and development, increased significantly. Cash and cash equivalents at the end of the period were $10,501,714.

CervoMed reported a net loss of $4.8 million for the third quarter of 2024, compared to a net income of $2.2 million for the same period in 2023. As of September 30, 2024, CervoMed had approximately $46.7 million in cash, cash equivalents and marketable securities.

CervoMed reported its financial results for the second quarter ended June 30, 2024, highlighting the completion of enrollment in the RewinD-LB Phase 2b trial and remaining on track to report topline data in December 2024. The company's cash position was strong due to a private placement, providing runway through 2025.

CervoMed reported its Q1 2024 financial results, highlighting the progress of the RewinD-LB Phase 2b clinical trial for neflamapimod in DLB patients, expected to complete enrollment in Q2 2024 with topline data anticipated in Q4 2024. The company completed a private placement of up to $149.4 million in early Q2 2024.

CervoMed reported its financial results for Q4 and full year 2023, highlighting advancements in their business, including a NASDAQ listing and the appointment of Joshua Boger, Ph.D., as Chair of the Board. The company is focused on the RewinD-LB Phase 2b trial for neflamapimod in DLB patients, with topline data expected in Q4 2024.

CervoMed reported a net income of $2.2 million for the third quarter of 2023, driven by a noncash gain from the conversion of convertible notes upon the merger. The company's cash position is expected to fund operations through the end of 2024, with key data expected from the RewinD-LB trial.

Diffusion Pharmaceuticals is actively pursuing a strategy to deliver stockholder value, including a possible sale, merger, or recapitalization. The company is in active bidding stage but the Board rejected an unsolicited offer from a LifeSci Capital client as inadequate, leading to a proxy contest.

Diffusion Pharmaceuticals reported positive results from its Altitude Trial and aligned with the FDA on an innovative GBM Trial design. The company ended the quarter with $28.5 million in cash, cash equivalents and marketable securities, expected to fund operations into the first quarter of 2024.

Diffusion Pharmaceuticals reported its Q1 2022 financial results, highlighting the completion of dosing in the Altitude Trial with topline data expected in June 2022, continued enrollment in the TSC ILD-DLCO Trial, expansion of the Scientific Advisory Board, and a solid cash position of $32.6 million. The company also regained compliance with the Nasdaq bid price rule.

Diffusion Pharmaceuticals reported cash and cash equivalents of $37.3 million as of December 31, 2021. The company is focused on advancing its lead product candidate, TSC, for hypoxic solid tumors.

Diffusion Pharmaceuticals reported a third-quarter operating loss of $12.6 million, which included a non-cash asset impairment charge of $8.6 million. Excluding this charge, the operating loss decreased by $1.3 million. The company's cash and cash equivalents totaled $40.3 million as of September 30, 2021, and they anticipate that they have sufficient cash to fund operations and capital expenditures through 2023.

Diffusion Pharmaceuticals reported its Q2 2021 financial results, highlighting the completion and announcement of topline results from the COVID-19 Trial and the first Oxygenation Trial. The company's development plan remains on track and they anticipate cash runway through 2023, including completion of TSC Phase 2b Program.

Diffusion Pharmaceuticals focused on progressing the development of its therapeutic, trans sodium crocetinate (TSC), and fortified its balance sheet through a $34.5 million equity raise during the first quarter. They completed dosing in a Phase 1 trial and a Phase 1b trial, and anticipate data analysis completion in the second quarter of 2021.

Diffusion Pharmaceuticals reported its 2020 financial results, highlighting a transformational year with a strengthened management team, advancement of its TSC development, and enhanced financial stability through multiple offerings.

Diffusion Pharmaceuticals reported financial results for the third quarter of 2020, highlighting a strengthened leadership team, $21.9 million in cash and cash equivalents, and progress in the clinical trial evaluating TSC in COVID-19 patients.

Diffusion Pharmaceuticals reported financial results for the second quarter of 2020. The company had $25.6 million in cash and cash equivalents as of June 30, 2020. They sold common stock raising $10.3 million and also raised $7.6 million from the exercise of outstanding warrants, for net proceeds of $17.9 million during the reporting period.

Diffusion Pharmaceuticals reported its first quarter 2020 financial results, highlighting the FDA's accelerated review for their IND application to study TSC in COVID-19 related ARDS, a delay in their Phase 2 on-ambulance stroke trial due to the pandemic, and continued partnership efforts for their Phase 3 INTACT trial. The company's cash position is expected to fund operations into the third quarter of 2021.

Diffusion Pharmaceuticals announced the retirement of Chief Science Officer John L. Gainer, who will continue to serve as an advisor and board member. The company has begun searching for a Chief Medical Officer to replace the Chief Science Officer position.